Vorinostat in solid and hematologic malignancies

David Siegel, Mohamad Hussein, Chandra Belani, Francisco Robert, Evanthia Galanis, Victoria M. Richon, José Garcia-Vargas, Cesar Sanz-Rodriguez, Syed Rizvi

Research output: Contribution to journalArticle

108 Citations (Scopus)

Abstract

Vorinostat (Zolinza), a histone deacetylase inhibitor, was approved by the US Food and Drug Administration in October 2006 for the treatment of cutaneous manifestations in patients with cutaneous T-cell lymphoma who have progressive, persistent or recurrent disease on or following two systemic therapies. This review summarizes evidence on the use of vorinostat in solid and hematologic malignancies and collated tolerability data from the vorinostat clinical trial program. Pooled vorinostat clinical trial data from 498 patients with solid or hematologic malignancies show that vorinostat was well tolerated as monotherapy or combination therapy. The most commonly reported drug-related adverse events (AEs) associated with monotherapy (n = 341) were fatigue (61.9%), nausea (55.7%), diarrhea (49.3%), anorexia (48.1%), and vomiting (32.8%), and Grade 3/4 drug-related AEs included fatigue (12.0%), thrombocytopenia (10.6%), dehydration (7.3%), and decreased platelet count (5.3%). The most common drug-related AEs observed with vorinostat in combination therapy (n = 157, most of whom received vorinostat 400 mg qd for 14 days) were nausea (48.4%), diarrhea (40.8%), fatigue (34.4%), vomiting (31.2%), and anorexia (20.4%), with the majority of AEs being Grade 2 or less. In Phase I trials, combinations with vorinostat were generally well tolerated and preliminary evidence of anticancer activity as monotherapy or in combination with other systemic therapies has been observed across a range of malignancies. Ongoing and planned studies will further evaluate the potential of vorinostat in combination therapy, including combinations with radiation, in patients with diverse malignancy types, including non-small-cell lung cancer, glioblastoma multiforme, multiple myeloma, and myelodysplastic syndrome.

Original languageEnglish (US)
Article number31
JournalJournal of Hematology and Oncology
Volume2
DOIs
StatePublished - Sep 2 2009

Fingerprint

Hematologic Neoplasms
Drug-Related Side Effects and Adverse Reactions
Fatigue
Anorexia
Nausea
Vomiting
Diarrhea
Therapeutics
vorinostat
Clinical Trials
Skin Manifestations
Cutaneous T-Cell Lymphoma
Histone Deacetylase Inhibitors
Myelodysplastic Syndromes
United States Food and Drug Administration
Glioblastoma
Multiple Myeloma
Platelet Count
Dehydration
Non-Small Cell Lung Carcinoma

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research
  • Molecular Biology
  • Medicine(all)

Cite this

Siegel, D., Hussein, M., Belani, C., Robert, F., Galanis, E., Richon, V. M., ... Rizvi, S. (2009). Vorinostat in solid and hematologic malignancies. Journal of Hematology and Oncology, 2, [31]. https://doi.org/10.1186/1756-8722-2-31

Vorinostat in solid and hematologic malignancies. / Siegel, David; Hussein, Mohamad; Belani, Chandra; Robert, Francisco; Galanis, Evanthia; Richon, Victoria M.; Garcia-Vargas, José; Sanz-Rodriguez, Cesar; Rizvi, Syed.

In: Journal of Hematology and Oncology, Vol. 2, 31, 02.09.2009.

Research output: Contribution to journalArticle

Siegel, D, Hussein, M, Belani, C, Robert, F, Galanis, E, Richon, VM, Garcia-Vargas, J, Sanz-Rodriguez, C & Rizvi, S 2009, 'Vorinostat in solid and hematologic malignancies', Journal of Hematology and Oncology, vol. 2, 31. https://doi.org/10.1186/1756-8722-2-31
Siegel D, Hussein M, Belani C, Robert F, Galanis E, Richon VM et al. Vorinostat in solid and hematologic malignancies. Journal of Hematology and Oncology. 2009 Sep 2;2. 31. https://doi.org/10.1186/1756-8722-2-31
Siegel, David ; Hussein, Mohamad ; Belani, Chandra ; Robert, Francisco ; Galanis, Evanthia ; Richon, Victoria M. ; Garcia-Vargas, José ; Sanz-Rodriguez, Cesar ; Rizvi, Syed. / Vorinostat in solid and hematologic malignancies. In: Journal of Hematology and Oncology. 2009 ; Vol. 2.
@article{8b375d3b1b124a8da03e52dc6a095877,
title = "Vorinostat in solid and hematologic malignancies",
abstract = "Vorinostat (Zolinza), a histone deacetylase inhibitor, was approved by the US Food and Drug Administration in October 2006 for the treatment of cutaneous manifestations in patients with cutaneous T-cell lymphoma who have progressive, persistent or recurrent disease on or following two systemic therapies. This review summarizes evidence on the use of vorinostat in solid and hematologic malignancies and collated tolerability data from the vorinostat clinical trial program. Pooled vorinostat clinical trial data from 498 patients with solid or hematologic malignancies show that vorinostat was well tolerated as monotherapy or combination therapy. The most commonly reported drug-related adverse events (AEs) associated with monotherapy (n = 341) were fatigue (61.9{\%}), nausea (55.7{\%}), diarrhea (49.3{\%}), anorexia (48.1{\%}), and vomiting (32.8{\%}), and Grade 3/4 drug-related AEs included fatigue (12.0{\%}), thrombocytopenia (10.6{\%}), dehydration (7.3{\%}), and decreased platelet count (5.3{\%}). The most common drug-related AEs observed with vorinostat in combination therapy (n = 157, most of whom received vorinostat 400 mg qd for 14 days) were nausea (48.4{\%}), diarrhea (40.8{\%}), fatigue (34.4{\%}), vomiting (31.2{\%}), and anorexia (20.4{\%}), with the majority of AEs being Grade 2 or less. In Phase I trials, combinations with vorinostat were generally well tolerated and preliminary evidence of anticancer activity as monotherapy or in combination with other systemic therapies has been observed across a range of malignancies. Ongoing and planned studies will further evaluate the potential of vorinostat in combination therapy, including combinations with radiation, in patients with diverse malignancy types, including non-small-cell lung cancer, glioblastoma multiforme, multiple myeloma, and myelodysplastic syndrome.",
author = "David Siegel and Mohamad Hussein and Chandra Belani and Francisco Robert and Evanthia Galanis and Richon, {Victoria M.} and Jos{\'e} Garcia-Vargas and Cesar Sanz-Rodriguez and Syed Rizvi",
year = "2009",
month = "9",
day = "2",
doi = "10.1186/1756-8722-2-31",
language = "English (US)",
volume = "2",
journal = "Journal of Hematology and Oncology",
issn = "1756-8722",
publisher = "BioMed Central",

}

TY - JOUR

T1 - Vorinostat in solid and hematologic malignancies

AU - Siegel, David

AU - Hussein, Mohamad

AU - Belani, Chandra

AU - Robert, Francisco

AU - Galanis, Evanthia

AU - Richon, Victoria M.

AU - Garcia-Vargas, José

AU - Sanz-Rodriguez, Cesar

AU - Rizvi, Syed

PY - 2009/9/2

Y1 - 2009/9/2

N2 - Vorinostat (Zolinza), a histone deacetylase inhibitor, was approved by the US Food and Drug Administration in October 2006 for the treatment of cutaneous manifestations in patients with cutaneous T-cell lymphoma who have progressive, persistent or recurrent disease on or following two systemic therapies. This review summarizes evidence on the use of vorinostat in solid and hematologic malignancies and collated tolerability data from the vorinostat clinical trial program. Pooled vorinostat clinical trial data from 498 patients with solid or hematologic malignancies show that vorinostat was well tolerated as monotherapy or combination therapy. The most commonly reported drug-related adverse events (AEs) associated with monotherapy (n = 341) were fatigue (61.9%), nausea (55.7%), diarrhea (49.3%), anorexia (48.1%), and vomiting (32.8%), and Grade 3/4 drug-related AEs included fatigue (12.0%), thrombocytopenia (10.6%), dehydration (7.3%), and decreased platelet count (5.3%). The most common drug-related AEs observed with vorinostat in combination therapy (n = 157, most of whom received vorinostat 400 mg qd for 14 days) were nausea (48.4%), diarrhea (40.8%), fatigue (34.4%), vomiting (31.2%), and anorexia (20.4%), with the majority of AEs being Grade 2 or less. In Phase I trials, combinations with vorinostat were generally well tolerated and preliminary evidence of anticancer activity as monotherapy or in combination with other systemic therapies has been observed across a range of malignancies. Ongoing and planned studies will further evaluate the potential of vorinostat in combination therapy, including combinations with radiation, in patients with diverse malignancy types, including non-small-cell lung cancer, glioblastoma multiforme, multiple myeloma, and myelodysplastic syndrome.

AB - Vorinostat (Zolinza), a histone deacetylase inhibitor, was approved by the US Food and Drug Administration in October 2006 for the treatment of cutaneous manifestations in patients with cutaneous T-cell lymphoma who have progressive, persistent or recurrent disease on or following two systemic therapies. This review summarizes evidence on the use of vorinostat in solid and hematologic malignancies and collated tolerability data from the vorinostat clinical trial program. Pooled vorinostat clinical trial data from 498 patients with solid or hematologic malignancies show that vorinostat was well tolerated as monotherapy or combination therapy. The most commonly reported drug-related adverse events (AEs) associated with monotherapy (n = 341) were fatigue (61.9%), nausea (55.7%), diarrhea (49.3%), anorexia (48.1%), and vomiting (32.8%), and Grade 3/4 drug-related AEs included fatigue (12.0%), thrombocytopenia (10.6%), dehydration (7.3%), and decreased platelet count (5.3%). The most common drug-related AEs observed with vorinostat in combination therapy (n = 157, most of whom received vorinostat 400 mg qd for 14 days) were nausea (48.4%), diarrhea (40.8%), fatigue (34.4%), vomiting (31.2%), and anorexia (20.4%), with the majority of AEs being Grade 2 or less. In Phase I trials, combinations with vorinostat were generally well tolerated and preliminary evidence of anticancer activity as monotherapy or in combination with other systemic therapies has been observed across a range of malignancies. Ongoing and planned studies will further evaluate the potential of vorinostat in combination therapy, including combinations with radiation, in patients with diverse malignancy types, including non-small-cell lung cancer, glioblastoma multiforme, multiple myeloma, and myelodysplastic syndrome.

UR - http://www.scopus.com/inward/record.url?scp=69249209745&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=69249209745&partnerID=8YFLogxK

U2 - 10.1186/1756-8722-2-31

DO - 10.1186/1756-8722-2-31

M3 - Article

C2 - 19635146

AN - SCOPUS:69249209745

VL - 2

JO - Journal of Hematology and Oncology

JF - Journal of Hematology and Oncology

SN - 1756-8722

M1 - 31

ER -